TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Rosiglitazone to Treat Asthma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to comprehend and grant a witnessed, written informed consent~* Must be greater than 19 years old~* Must be able to swallow a tablet~* Female participants must have a negative urine pregnancy test at visit 1 and throughout duration of the study~* Must have a history of physician diagnosed asthma~* Must have a baseline FEV1 \>60% predicted~* Must be able to perform pulmonary function testing~* Must have methacholine-induced decrease in FEV1 of 20%~* Must be capable of withholding medications that may affect the methacholine challenge test~* Must be able to withstand a 30 day washout period for all inhaled corticosteroids~* Must be able to attend all office visits, 4 weeks apart for 12 weeks. Each visit will last approximately 2-3 hours~Exclusion Criteria:~* Age 18 or younger~* FEV1 \<60% predicted value~* History or presence of significant renal, hepatic,neurologic, cardiovascular, hematologic, cerebrovascular, respiratory, endocrine, gastrointestinal, or collagen vascular disorder that in the Investigator's opinion could interfere with the study or require medical attention that would interfere with the study.~* History of cancer other than basal cell skin cancer~* History of hypoglycemia~* Current smokers, greater than 10 pack year history, or patients quitting less than 1 year prior to screening~* History within the past year of excessive alcohol intake or drug addiction~* History of respiratory infection requiring treatment with an antibiotic within 2 week prior to visit 1~* Chronic intermittent use of inhaled, oral, intra-muscular, topical or intravenous corticosteroids within 4 weeks of visit 1~* Inability to perform consistent spirometry or nitric oxide exhalation~* Treatment with an experimental, non-approved drug, or investigational drug within the past 30 days~* Known hypersensitivity to rosiglitazone~* History of noncompliance to medical regimens and participants who are considered to be potentially unreliable

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe idiopathic RLS~* symptoms occur predominantly in the evening~* symptoms interfere with sleep onset or maintenance~Exclusion Criteria:~* Any secondary RLS~* require treatment for daytime RLS symptoms~* symptomatic neuropathies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): investigational treatment
- 3 (Type: EXPERIMENTAL): investigational treatment
- 4 (Type: EXPERIMENTAL): investigational treatment
- 5 (Type: EXPERIMENTAL): investigational treatment
- 6 (Type: EXPERIMENTAL): investigational treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven breast carcinoma evaluated for HER 2 status and immune status~* Locally advanced carcinoma (UICC stage II-III)~* Age \< 70 years~* measurable lesions~* ECOG Performance Status 0-2~* Life expectancy \> 3 months~* Adequate bone marrow and hepatic functions~* Creatinine Clearance \> 40 ml/min~* Written informed consent~* Patients must be accessible for treatment and follow up.~Exclusion Criteria:~* Prior chemotherapy or hormonal treatments~* Brain metastases.~* Past or current history of neoplasm other than curatively treated.~* Concurrent treatment with other experimental drugs.~* Left Ventricular Ejection Fraction (LVEF) \<50 %~* History of significant neurological or psychiatric disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Locally advanced HER2+ breast cancer pts (Type: EXPERIMENTAL): HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision
- Locally advanced HER2- breast cancer pts (Type: EXPERIMENTAL): HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Prophylaxis of Gastric Varix Bleed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GOV2 with eradicated esophageal varix or IGV1, who had never bled from gastric varix were included.~Exclusion Criteria:~* Only esophageal varix, GOV1 with GOV2, acute bleed or past history of bleed from gastric varix, contraindications to beta-blocker therapy and cyanoacrylate injection.~* Prior injection of cyanoacrylate or sclerotherapy or variceal ligation or transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration or balloon-occluded endoscopic injection sclerotherapy of gastric varix for prevention of bleeding from GV~* Patients already on beta-blocker or nitrates~* Undetermined origin of bleeding from esophageal varix or gastric varix~* Hepatic encephalopathy grade III/IV~* Hepatorenal syndrome~* Hepatocellular carcinoma~* Presence of deep jaundice (serum bilirubin \> 10 mg/dl)~* Uremia~* Cerebrovascular accident~* Cardiorespiratory failure~* Pregnancy and patients not giving informed consent for endoscopic procedures

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic Cyanoacrylate injection (Type: ACTIVE_COMPARATOR): Endoscopic injection of cyanoacrylate in the gastric varix until obturation
- No Intervention (Type: NO_INTERVENTION): No treatment offered for gastric varix
- Beta-blocker (propranolol) (Type: OTHER): Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive postmenopausal women~* Diagnosed hypertension (grade 1 or 2 according to ESH/ESC 2013 guidelines)~Exclusion Criteria:~* breast cancer in a first-degree relative~* hyperplasia diagnosed by endometrial biopsy,~* history of thromboembolic diseases,~* current or history of use of estrogen-progestin therapy or contraceptives~* diabetes,~* kidney failure,~* thyroid disease,~* heart and other chronic diseases (secondary hypertension, atrial fibrillation)

- Gender: FEMALE
- Minimum Age: 49 Years
- Maximum Age: 53 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control group consisted of 40 postmenopausal women with normal blood pressure.
- Hypertensive women group receiving hydrochlorothiazide (Type: EXPERIMENTAL): Patients received hydrochlorothiazide 25 mg/day p.o. for 1 year.
- Hypertensive women group receiving perindopril. (Type: EXPERIMENTAL): Patients received perindopril 4 mg/day p.o for 1 year.
- Hypertensive women group receiving hydrochlorothiazide and EPT (Type: EXPERIMENTAL): Patients received hydrochlorothiazide 25 mg/day p.o. and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
- Hypertensive women group receiving perindopril and EPT. (Type: EXPERIMENTAL): Patients received perindopril 4 mg/day p.o and estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year
- Hipotensive women group receiving EPT. (Type: EXPERIMENTAL): Patients received estrogen-progestin therapy- transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First-ever stroke according to the World Health Organisation criteria (previous transient ischaemic attack or clinically silent infarct on CT/MRI is not counted as previous stroke)~* CT/MRI scan required to classify ischaemic / haemorrhagic stroke~* Patient recruited 2-12 weeks after stroke~* Modified Ashworth Spasticity Score 1+ or above in either elbow or wrist joint~Exclusion Criteria:~* The patient has bleeding disturbances or having used coumarin derivatives~* The patient is currently receiving drugs affecting neuromuscular transmission~* Co-existing severe systemic illness which may adversely affect the functional outcome~* Pre-existing neuromuscular junction disease or any neurogenic disorders which can interfere with spasticity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dysport
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health~* Received primary dose of M-M-R II at less than or equal to 12 months of age~* Received primary dose of Varivax at less than or equal to 12 months of age~* Negative history of varicella, zoster, measles, mumps, and rubella~Exclusion Criteria:~* history of receiving more than once dose of M-M-R II or Varivax~* Any immune impairment or deficiency~* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination~* Vaccination with an inactive vaccine with in the past 14 days~* Vaccination with a live vaccine within the past 30 days~* Receipt of immune globulin, or blood product in the past 5 months

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): ProQuad + Placebo
- 2 (Type: ACTIVE_COMPARATOR): M-M-R II + Placebo
- 3 (Type: ACTIVE_COMPARATOR): M-M-R II + Varivax

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes, currently treated with one or more oral hypoglycemic agent~* HbA1c: At least 8.0%~Exclusion Criteria:~* Impaired hepatic, renal or cardiac function

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosis of Ulcerative Colitis for 3 or more months.~* Ulcerative colitis must be active beyond the rectum.~* Must active Ulcerative Colitis with a Total Mayo Score of 6 to 12 points~Exclusion Criteria:~* Pregnant or breast feeding.~* Diagnosis of indeterminate colitis or Crohn's Disease~* Subjects with history of colonic or small bowel obstruction or resection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Drug Dose Level 1 (Type: EXPERIMENTAL): None
- Drug Dose Level 2 (Type: EXPERIMENTAL): None
- Drug Dose Level 3 (Type: EXPERIMENTAL): None
- Drug Dose Level 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiomyopathy in DMD: Lisinopril vs. Losartan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duchenne muscular dystrophy patients of all ages~* Null mutation of the dystrophin gene or muscle with \<5% dystrophin~* Doppler echocardiogram with ejection fraction (EF) \<55% within 30 days of enrollment~* Ability to cooperate for testing~* Glucocorticoid treatment acceptable including daily or weekend administration of prednisone or deflazacort~Exclusion Criteria:~* Patients with EF 55% or greater~* Patients with EF \<40% after washout~* Patients taking \>5 mg lisinopril, or \>25 mg losartan or \>5 mg enalapril~* Skeletal deformities or pulmonary anatomical variants that preclude consistent measures of Doppler echocardiography

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lisinopril (Type: ACTIVE_COMPARATOR): None
- Losartan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe cognitive impairment (complete dependency in all activities of daily living (ADLs)~* Diagnosis of Alzheimer's disease, vascular dementia,or frontotemporal dementia~* Score\> 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s) interfering in the provision of care~Exclusion Criteria:~* Alternate etiologies for increased tone~* Botulinum toxin 6 months preceding the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): Saline injection up to 5 cc in arm with paratonia (one time injection)
- Botulinum Toxin (Type: ACTIVE_COMPARATOR): Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EC PK in Women With Normal and Obese BMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-45 years~* English-speaking~* BMI 18.5-24.9 kg/m2 or obese BMI 30.0-39.9 kg/m2~* Regular menstrual cycles~* No use of medroxyprogesterone acetate at least 6 months prior to study enrollment, unless resumption of two menstrual cycles~* No use of levonorgestrel intrauterine system (levonorgestrel-IUS), etonogestrel implant or combined hormonal contraception at least one month prior to the study and resumption of one menstrual cycle~* Women who are postpartum or post-abortion will be included if they have had at least one menstrual cycle since their last pregnancy~Exclusion Criteria:~* Prior allergic reaction to LNG-EC or UPA-EC~* Use of hormonal emergency contraception within the past month~* Women who are currently pregnant or who are currently breastfeeding~* History of cancer other than non-melanoma skin cancer~* Medical or surgical conditions or conditions requiring therapies known to impact sex steroid production or metabolism~  * Use of HAART therapy for management of HIV infection~ * Concomitant use of CYP3A4 inducers like rifampin, barbiturates, carbamazepine, lamotrigine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St. John's Wort and topiramate~* Current participation in any other trial of an investigational medicine or device in the three months leading up to this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Normal-BMI (Type: OTHER): Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
- Obese-BMI (Type: OTHER): Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 or older.~2. Histologically or cytologically confirmed cholangiocarcinoma which was considered to be advanced/metastatic or surgically unresectable by the investigator through image examination.~3. Radiographically measurable disease per RECIST v 1.1~4. Documentation of FGFR2 rearrangement.~5. Documented disease progression after at least 1 line of prior systemic therapy.~6. ECOG performance status of 0\~1.~7. Life expectancy ≥12 weeks.~Exclusion Criteria:~1. Prior receipt of a selective FGFR inhibitor.~2. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).~3. Currently evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.~4. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemigatinib in patients with advanced/metastatic or surgically (Type: EXPERIMENTAL): Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete